GLENZA 40MG

Description

Glenza 40mg tablets are majorly indicated for prostate carcinoma, which contains Enzalutamide, as an active component considered as non-steroidal anti-androgen medication.

Glenza 40mg is a prescription medicine, which can be used under the guidance of medical practitioners.

Glenza 40mg tablet indication

The primary usage of Glenza 40mg tablet is contains in the specific treatment of metastatic castration resistant prostate cancer (mCRPC), taken orally.

The anti-androgen effect exhibits by obstruct the testosterone production by interfere with androgen synthesis, the hormone which is responsible for tumor cell growth.

Glenza 40mg is majorly used to treat prostate cancer in men.

Dosing conditions of Glenza 40mg

The usual prescribed dosage of Glenza is 160mg as a single dose by taking with or without food.

Glenza is available in the strength of 40mg; four tablets of Glenza should be administered at a same time.

Glenza tablet should not crush, not chew taken with glass of water.

Dose adjustment

In patients with ≥ grade III toxicity:  Glenza 40mg therapy should be refuse for one week or the symptoms should be reduced to grade II, then restart with same dose or decreased to 80mg or 120mg

Strong CYP2C8 inhibitors: While combining with Glenza tablet, the dosage should be modified by reducing to 80mg as a single dose or avoid this combination.

Strong CYP3A4 inducers: Co administration of Glenza with Strong CYP3A4 inducers, the dosage of Glenza tablet increased up to 240mg or stop this combination.

Glenza 40mg over dosage

In the case of over dosage of Glenza tablets, causes severe seizures.

If over dosage is occurring, immediately stop the therapy and maintain the safety measures.

In dose acceleration study, seizure does not occur at ≤ 240mg daily.

Seizures may report in the dose of 360mg, 480mg & 600mg at high risk

Glenza 40mg works as

Prostate carcinoma is developed by using male hormone known as androgen.

Testosterone is the one of the major hormones secreted by testes and adrenal glands

Glenza containing Enzalutamide will interfere with testosterone production, causes tumor cell growth depletion.

Glenza interfere with androgen receptor signaling transduction and leads to cancer cell lysis

Glenza 40mg ADME properties

Absorption

After receiving 160mg of Glenza for mCRPC, from median time to attain peak plasma concentration time at 1 hour (variation with 0.5 to 3 hours).

Food does not cause any alteration in absorption of Glenza tablets.

Distribution

Maximum plasma protein bounding capacity of Glenza tablets is occurs as 97% to 98%

Metabolism

Two most prominent cytochrome isoenzymes are involved in metabolism of Glenza tablets;

The isoenzymes like CYP2C8 & CYP3A4; whereas CYP2C8 is essential for production of N-desmethyl Enzalutamide which is an active metabolite of Enzalutamide.

Excretion

Glenza tablets go through elimination by hepatic metabolism

Major route of elimination;

71% in urine; 14% in feces

The terminal half-life period of Glenza tablets is 5.8 days (range at 2.8 to 10.2 days); N-desmethyl Enzalutamide has half-life period of relatively 7.8 to 8.6 days.

Glenza 40mg causes some side effects

Some side effects during the therapy using with Glenza,

Hypertension & hot flush, Dizziness, headache, Asthenia conditions, Peripheral edema, Spinal cord compression, paresthesia, Mental impairment, Hypesthesia, Respiratory tract infections, Hematuria, Pollakiuria, Dry skin, Back pain, Arthralgia, Muscular weakness, pain, Diarrhea, Pruritus, Neutropenia, Thrombocytopenia, Increasing bilirubin level, Epistaxis, Infections like sepsis, Fall associated injuries like fractures, joint injury, and hematomas, Hallucinations.

Glenza 40mg contraindication occurs as

Glenza tablets are contraindicated to pregnancy condition, which may cause fetal harm leads to death.

An Anaphylactic reaction happens, if patients are contraindicated to the ingredient present in Glenza tablets.

Glenza 40mg storage conditions

Glenza tablet container should be stored at the temperature of 20^oC to 25^oC (68^oF to 77^oF).

Keep the container in cool and dry place

Protect from light.

Glenza 40mg warning and precautions

During the treatment with Glenza tablets, patient may suffer with some adverse effects like;

Posterior reversible encephalopathy syndrome

Seizures

In PRES, some neurological disorders occur in patients. It may overcome by providing safety measures or discontinue the therapy as soon as possible.

PRES is recognized by using MRI

In seizures, patient must counsel about this adverse reaction before starting the therapy. Stop the therapy if possible.

Spermatogenesis occurs which may interfere with male fertility leads to hypo spermatogenesis.

In androgen depletion therapy, may have increase exposure of cardiovascular disease like worsening hypertension.

Glenza 40mg interact with some drugs like

Glenza combined with CYP2C8 strong inhibitors, causes elevation of plasma concentration time curve of Enzalutamide and its active metabolite. So avoid this combination, otherwise dosage of Glenza should be reduced to 80mg.

Glenza with CYP2C8 strong inducers causes variation in plasma exposure of Glenza, to minimize this problem to avoid this concomitant.

Co administration of Glenza tablets with strong inhibitors or CYP3A4, leads to elevate the AUC of Enzalutamide and its metabolite.

CYP3A4 strong inducers example like; phenytoin, Phenobarbital, carbamazepine etc combines with Glenza tablets causes depletes the plasma exposure of Glenza.

Moderate CYP3A4 inducers like Bosentan, efavirenz, modafinil, st Johns wort causes decreasing the plasma concentration of Glenza tablet.

Glenza tablets are strong CYP3A4 inducers and moderate CYP2C8 & CYP2C19.

CYP3A4 strong inducers like Midazolam, CYP2C8 inducers like warfarin, & CYP2C19 inducers like Omeprazole with Glenza causes reducing the plasma risk of Midazolam, warfarin & Omeprazole.

Glenza 40mg specifically used in

Pregnancy

Pregnancy category of Glenza tablet is D

Glenza is contraindicated to pregnancy; it may cause fetal harm even to death.

Lactation

Breast feeding is not suggested, Glenza is contraindicated in lactation

Glenza 40mg missed dose

Glenza 40mg is a chem. Drug, used in prostate cancer. Glenza tablet should not be self-medicated, used by the patients only after getting advice from the medical oncologist.

If patient missed a dose, must consult with the physician and follow the instructions as per the guidance of medical adviser, the missed dose should be taken within a time or the missed dose should be avoid and follow the regular schedule.